Bicycle Therapeutics plc (BCYC) Balance Sheet

The decline is driven by sustained operating outflows against a shrinking equity base, with equity dropping from $873.8M to $505.3M over the same period. The pace of erosion suggests the company's runway is the key variable investors should monitor, since the balance sheet is weakening over time rather than stabilizing. Reported figures alone do not indicate whether future financing or partnership inflows will offset this trend.

A current ratio above 12 indicates short-term obligations are minimal relative to liquid assets, which reduces near-term solvency concern. However, the ratio tells little about burn duration, and the trend in cash balances implies a finite runway absent new capital or collaboration income. Investors should monitor quarterly cash consumption against the remaining balance rather than relying on the headline liquidity ratio.

Debt was modest throughout most of the period, with a brief rise to $42.7M in 2024Q2 before reducing to single-digit millions in 2025. The low leverage suggests limited refinancing pressure, so the more relevant balance sheet risk is equity depletion rather than debt service. The reported debt levels do not by themselves reveal lease commitments or other obligations that may fall outside this figure.

Equity has been preserved largely by external capital rather than earnings, as the accumulated deficit widens each quarter with net losses. Stock-based compensation has been a recurring non-cash charge, which adds to the deficit while diluting ownership. This pattern indicates equity quality depends on continued capital access instead of internally generated value.